MarketCap
Facebook
X
Telegram
Apellis Pharmaceuticals Accounts Receivables | APLS
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Apellis Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 366 M | 265 M | 206 M | 7.73 M | 10.1 M | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 366 M | 7.73 M | 171 M |
Quarterly Accounts Receivables Apellis Pharmaceuticals
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 440 M | 346 M | 214 M | 235 M | 265 M | 279 M | 304 M | 268 M | 206 M | 169 M | 111 M | 31.5 M | 7.73 M | 8.09 M | 7.52 M | 6.33 M | 10.1 M | 3.52 M | 719 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 440 M | 719 K | 153 M |
Accounts Receivables of other stocks in the Biotechnology industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aclaris Therapeutics
ACRS
|
318 K | $ 5.32 | 0.09 % | $ 652 M |  USA |
 |
ADC Therapeutics SA
ADCT
|
29.1 M | $ 1.05 | 0.46 % | $ 133 M |  Schweiz |
 |
Agenus
AGEN
|
1.83 M | $ 7.21 | 0.7 % | $ 214 M | USA |
 |
Akebia Therapeutics
AKBA
|
47 M | $ 0.92 | 1.64 % | $ 237 M | USA |
 |
Alkermes plc
ALKS
|
334 M | $ 46.07 | 0.09 % | $ 7.59 B |  Irlanda |
 |
Alnylam Pharmaceuticals
ALNY
|
778 M | $ 239.36 | 0.46 % | $ 31.4 B | USA |
 |
Altimmune
ALT
|
1.22 M | $ 3.24 | 0.31 % | $ 285 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
144 M | $ 23.95 | 1.31 % | $ 1.12 B | USA |
 |
AnaptysBio
ANAB
|
33.8 M | $ 54.31 | 0.15 % | $ 1.56 B | USA |
 |
Anika Therapeutics
ANIK
|
23.7 M | $ 20.84 | 0.24 % | $ 299 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
281 M | $ 73.59 | 2.05 % | $ 1.48 B | USA |
 |
Aptevo Therapeutics
APVO
|
5.22 M | $ 1.72 | 0.58 % | $ 543 K | USA |
 |
Aquestive Therapeutics
AQST
|
17.8 M | $ 4.82 | 0.21 % | $ 515 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
5.56 M | $ 15.6 | 0.25 % | $ 427 M |  Israel |
 |
Armata Pharmaceuticals
ARMP
|
25 K | $ 4.07 | 2.21 % | $ 147 M | USA |
 |
Assembly Biosciences
ASMB
|
974 K | $ 25.48 | 0.54 % | $ 286 M | USA |
 |
AbbVie
ABBV
|
12.6 B | $ 262.51 | 0.01 % | $ 464 B | USA |
 |
Atara Biotherapeutics
ATRA
|
1.25 M | $ 10.11 | 7.1 % | $ 127 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
41.5 M | $ 16.96 | 5.15 % | $ 2.28 B |  Canada |
 |
Autolus Therapeutics plc
AUTL
|
24 M | $ 1.87 | 0.53 % | $ 498 M |  Britain |
 |
Axon Enterprise
AXON
|
18.1 M | $ 468.42 | 5.96 % | $ 36.6 B | USA |
 |
Axsome Therapeutics
AXSM
|
224 M | $ 211.97 | 3.87 % | $ 10.5 B | USA |
 |
Aytu BioScience
AYTU
|
31.2 M | $ 1.97 | 0.5 % | $ 12.4 M | USA |
 |
BridgeBio Pharma
BBIO
|
139 M | $ 68.3 | 0.1 % | $ 13.1 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
2.04 M | $ 3.64 | 0.68 % | $ 252 M | Britain |
 |
Biogen
BIIB
|
1.34 B | $ 216.01 | 0.42 % | $ 31.6 B | USA |
 |
AbCellera Biologics
ABCL
|
39.4 M | $ 11.67 | 2.28 % | $ 3.49 B | Canada |
 |
Benitec Biopharma
BNTC
|
4 K | $ 11.04 | 0.9 % | $ 514 M | USA |
 |
Clovis Oncology
CLVS
|
26.9 M | - | -7.23 % | $ 13 M | USA |
 |
Chimerix
CMRX
|
57 K | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
218 K | - | - | $ 401 M | USA |
 |
Catalyst Biosciences
CBIO
|
31.1 M | $ 17.18 | 1.7 % | $ 1.53 B | USA |
 |
C4 Therapeutics
CCCC
|
2.4 M | $ 3.45 | 0.58 % | $ 286 M | USA |